Press Releases

March 31, 2021

ProMIS Neurosciences Announces Fiscal Year 2020 Results

March 22, 2021

ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

Press Archives

In the News

November 4, 2020

Pharma Boardroom – Aducanumab edges closer to Potential Approval: Next up, the Advisory Committee meeting

September 23, 2020

Pharma Boardroom – Aducanumab: On the Regulatory Home Stretch in the USA

News Archives

Podcasts

Presentations

January 27, 2020

Sachs Neuroscience Innovation Forum Presentation

November 6, 2019

ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform

Presentations Archives

Videos

November 6, 2019

ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform

August 6, 2019

Dr. James Kupiec’s update from AAIC 2019: Demonstrating Early Proof-of-Concept with Biomarkers and Focused Patient Populations

July 18, 2019

ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019 

Video Archives